Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rameau et al., 2007), such as in uncontrolled epilepsy (Sumadewi et al., 2023) and stroke (Qin et al., 2022)
If anemia persists despite adequate iron stores and hemoglobin remains below 10 g/dL, erythropoiesis-stimulating agents (ESAs) may be initiated to support red blood cell production ( 10 , 11 )
Unlike traditional weight loss medications, AOD-9604 works by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation), making it a safe and effective option for reducing stubborn fat deposits while preserving lean muscle mass